NCT00409760已完成3 期
A Randomized, Double-blind, Multicenter, Multifactorial, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Valsartan and Amlodipine Combined and Alone in Hypertensive Patients.
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- Novartis
- 入组人数
- 1,930
- 试验地点
- 1
- 主要终点
- Change from baseline (Visit 2) in mean sitting diastolic blood pressure at trough (Wk 4 and Wk 8)
研究概览
简要总结
This trial will compare valsartan and amlodipine combination therapies to both valsartan and amlodipine, and placebo for the treatment of hypertension.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Outpatients 18 years and older.
- •Male or female patients are eligible.
- •Female patients must be either post-menopausal for one year or surgically sterile, or using effective contraceptive methods such as barrier method with spermicide or an intra-uterine device. Hormonal contraceptive use is disallowed.
- •Patients with mild to moderate essential diastolic hypertension (grades 1 and 2 WHO classification) measured by calibrated standard sphygmomanometer.
- •Patients must have a MSDBP >= 90 mmHg and < 110 mmHg at Visit 1 (week -2 to -4), and a MSDBP >= 95 mmHg and < 110 mmHg at Visit 2 (week 0).
- •Patients must have an absolute difference of =< 10 mmHg in their average sitting diastolic blood pressure between Visits 1 and
- •Patients who are eligible and able to participate in the study, and who consent to do so after the purpose and nature of the investigation has been clearly explained to them (written informed consent).
排除标准
- •Severe hypertension (grade 3 WHO classification; MSDBP >=110 mmHg diastolic and/or MSSBP >= 180 mmHg systolic).
- •Inability to discontinue all prior anti-hypertensive medications safely for a period of 14 weeks).
- •Known Keith-Wagener grade III or IV hypertensive retinopathy.
- •History of hypertensive encephalopathy or cerebrovascular accident at anytime prior to Visit 1 (week -2 to -4).
- •Transient ischemic cerebral attack during the last 12 months prior to Visit 1 (week -2 to -4).
- •Evidence of a secondary form of hypertension, such as coarctation of the aorta, hyperaldosteronism, unilateral renal artery stenosis, or pheochromocytoma, etc.
- •Type 1 Diabetes Mellitus.
- •Type 2 Diabetes Mellitus with poor glucose control as defined by fasting glycosylated hemoglobin (HbA1c) >8% at Visit 1 (week -2 to -4).
- •Administration of any agent indicated for the treatment of hypertension within a minimum 4 weeks prior to randomization into the study (Visit 2, week 0), with the permitted exception of those anti-hypertensive medications requiring tapering down commencing at Visit 0 (week -4 to -6).
- •Known or suspected contraindications, including history of allergy to angiotensin receptor blockers or calcium channel blockers.
- •Other protocol-defined inclusion/exclusion criteria may apply
结局指标
主要结局
Change from baseline (Visit 2) in mean sitting diastolic blood pressure at trough (Wk 4 and Wk 8)
次要结局
- Sitting and standing pulse
- Change from baseline (Visit 2) in standing diastolic and systolic blood pressure at trough(Wk 4 and Wk 8)
- Change from baseline (Visit 2) in mean sitting systolic blood pressure at trough (Wk 4 and Wk 8)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
Safety and Efficacy of Valsartan and Amlodipine Combined and Alone in Hypertensive PatientsHypertensionNCT00409643Novartis1,259
已完成
3 期
Efficacy and Safety of Valsartan and Amlodipine (± HCTZ) in Adults With Moderate, Inadequately Controlled HypertensionHypertensionNCT00523744Novartis257
已完成
3 期
Efficacy/Safety of Valsartan Plus Amlodipine and Amlodipine Alone in Patients With HypertensionHypertensionNCT00413049Novartis698
已完成
3 期
Efficacy and Safety of Valsartan/Amlodipine in Patients With Mild to Moderate Essential HypertensionEssential HypertensionNCT01001572Novartis932
已完成
4 期
Efficacy of a Combination of Amlodipine/Valsartan on 24H Blood Pressure Control With One Nocturnal or Diurnal Intake a DayHypertensionNCT00700271Novartis Pharmaceuticals478